Both NOS2 inhibitor 1400W (Figure 7A) and PTIO (Figure 7B) significantly reduced the growth rate of siPDLIM2-treated ovarian cancer cells compared with control. This evidence concerns the gene NOS2 and ovarian carcinoma.